Supplementary Digital Content 4. Characteristics of study at the end of follow-up, and follow-up period

Treatment Variables	UFT		5-FU	
	n	%	n	%
Total	14,486	63.39	8,366	36.61
Disease recurrence				
Without	12,916	89.16	20,485	73.66
With	1,570	10.84	7,324	26.34
Mortality				
Without	12,704	87.70	23,520	84.58
With	1,782	12.30	4,289	15.42
Gender				
Male	8,690	59.99	5,064	60.53
Female	5,796	40.01	3,302	39.47
Age (years ± SD)	69.23 ± 14.22		69.29 ± 14.16	
Insured premium (NT$)				
<18,000	14,250	98.37	8,200	98.02
18,000-34,999	192	1.33	131	1.57
≧35,000	44	0.30	35	0.42
HTN				
Without	10,218	70.54	5,967	71.32
With	4,268	29.46	2,399	28.68
DM				
Without	11,611	80.15	6,679	79.84
With	2,875	19.85	1,687	20.16
COPD				
Without	13,541	93.48	7,826	93.55
With	945	6.52	540	6.45
CKD				
Without	13,679	94.43	7,928	94.76
With	807	5.57	438	5.24
IHD				
Without	12,996	89.71	7,544	90.17
With	1,490	10.29	822	9.83
CHD				

Without	13,789	95.19	7,960	95.15
With	697	4.81	406	4.85
Stroke				
Without	13,510	93.26	7,790	93.11
With	976	6.74	576	6.89
CCI_R	0.08 ± 0.47		0.07 ± 0.44	
Urbanization level				
1 (The highest)	4,691	32.38	2,678	32.01
2	6,731	46.47	3,874	46.31
3	978	6.75	562	6.72
4 (The lowest)	2,086	14.40	1,252	14.97
Level of care				
Hospital center	5,789	39.96	3,354	40.09
Regional hospital	6,316	43.60	3,595	42.97
Local hospital	2,381	16.44	1,417	16.94

UFT, uracil-tegafur; 5-FU, 5-Flurouracil; HTN, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; IHD, ischemic heart disease; CHD, congestive heart disease; CCI_R, Charlson comorbidity index removed cancer

Years of follow-up				
Treatment	**Min**	**Median**	**Max**	**Mean ± SD**
Oral uracil-tegafur	0.01	3.17	15.84	4.10 ± 3.75
Injection 5-Flurouracil	0.01	3.07	15.92	4.02 ± 3.67